scholarly journals Effects of oral care with tongue cleaning on coughing ability in geriatric care facilities: a randomised controlled trial

2016 ◽  
Vol 43 (12) ◽  
pp. 953-959 ◽  
Author(s):  
M. Izumi ◽  
K. Takeuchi ◽  
S. Ganaha ◽  
S. Akifusa ◽  
Y. Yamashita
2020 ◽  
pp. bjophthalmol-2019-315620
Author(s):  
Ryan Eyn Kidd Man ◽  
Alfred Tau Liang Gan ◽  
Marios Constantinou ◽  
Eva K Fenwick ◽  
Edith Holloway ◽  
...  

BackgroundTo assess the clinical and patient-centred effectiveness of a novel residential ocular care (ROC) model in Australian individuals residing in residential care.MethodsIn this prospective, multicentred, randomised controlled trial conducted in 38 Australian aged-care facilities (2015–2017), 178 visually impaired individuals living in residential care facilities (mean age ±SD: 83.9±8.6 years; 65.7% women) were cluster randomised to ROC (n=95) or usual care (n=83) pathways. The ROC arm comprised a tailored and comprehensive within-site eye examination and care rehabilitation pathway, while usual care participants were given a referral to an external eyecare provider. Outcomes included presenting distance and near visual acuity (PNVA); Rasch-transformed Reading, Emotional and Mobility scores from the Impact of Vision Impairment questionnaire; quality of vision (QoV comprising Rasch-transformed Frequency, Severity and Bother domains) scores; Euroqol-5-Dimensions (raw scores); Cornell Scale for Depression (raw scores) and 6-month falls frequency, assessed at baseline and 6 months post intervention. Within-group and between-group comparisons were conducted using linear mixed models, adjusted for baseline differences in characteristics between the two arms.ResultsAt 6 months, intention-to-treat analyses showed significant between-group improvements in ROC residents compared with usual care for PNVA, Emotional and QoV scores (all p<0.05) These significant findings were retained in per-protocol analyses. No other between-group changes were observed.ConclusionOur ROC model was effective in improving near vision, emotional well-being and perceived burden of vision-related symptoms in residential care dwellers in Australia with vision impairment. Future studies to evaluate the cost effectiveness and implementation of ROC in Australia are warranted.


The Lancet ◽  
2015 ◽  
Vol 385 (9978) ◽  
pp. 1623-1633 ◽  
Author(s):  
Anders Prestmo ◽  
Gunhild Hagen ◽  
Olav Sletvold ◽  
Jorunn L Helbostad ◽  
Pernille Thingstad ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e46509 ◽  
Author(s):  
Robert Booy ◽  
Richard I. Lindley ◽  
Dominic E. Dwyer ◽  
Jiehui K. Yin ◽  
Leon G. Heron ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. e032851
Author(s):  
Renly Lim ◽  
Luke Bereznicki ◽  
Megan Corlis ◽  
Lisa M Kalisch Ellett ◽  
Ai Choo Kang ◽  
...  

IntroductionMany medicines have adverse effects which are difficult to detect and frequently go unrecognised. Pharmacist monitoring of changes in signs and symptoms of these adverse effects, which we describe as medicine-induced deterioration, may reduce the risk of developing frailty. The aim of this trial is to determine the effectiveness of a 12-month pharmacist service compared with usual care in reducing medicine-induced deterioration, frailty and adverse reactions in older people living in aged-care facilities in Australia.Methods and analysisThe reducing medicine-induced deterioration and adverse reactions trial is a multicentre, open-label randomised controlled trial. Participants will be recruited from 39 facilities in South Australia and Tasmania. Residents will be included if they are using four or more medicines at the time of recruitment, or taking more than one medicine with anticholinergic or sedative properties. The intervention group will receive a pharmacist assessment which occurs every 8 weeks. The pharmacists will liaise with the participants’ general practitioners when medicine-induced deterioration is evident or adverse events are considered serious. The primary outcome is a reduction in medicine-induced deterioration from baseline to 6 and 12 months, as measured by change in frailty index. The secondary outcomes are changes in cognition scores, 24-hour movement behaviour, grip strength, weight, percentage robust, pre-frail and frail classification, rate of adverse medicine events, health-related quality of life and health resource use. The statistical analysis will use mixed-models adjusted for baseline to account for repeated outcome measures. A health economic evaluation will be conducted following trial completion using data collected during the trial.Ethics and disseminationEthics approvals have been obtained from the Human Research Ethics Committee of University of South Australia (ID:0000036440) and University of Tasmania (ID:H0017022). A copy of the final report will be provided to the Australian Government Department of Health.Trial registration numberAustralian and New Zealand Trials Registry ACTRN12618000766213.


2019 ◽  
Vol 48 (3) ◽  
pp. 373-380 ◽  
Author(s):  
Maria Crotty ◽  
Maggie Killington ◽  
Enwu Liu ◽  
Ian D Cameron ◽  
Susan Kurrle ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document